The US Department of Commerce is reportedly weighing whether to convert part of the subsidies granted to Intel and TSMC under the CHIPS and Science Act into equity stakes. Chung-Shu Wu, chairman of the Taiwan Institute of Economic Research (TIER), cautioned that such market intervention policies will inevitably undermine corporate investment confidence, weaken US innovation, and damage America’s long-term interests.

Intel is grappling with accelerating staff departures as CEO Pat Gelsinger pushes through sweeping restructuring efforts and cancels projects championed by his predecessor. The financially strained chipmaker is facing mounting losses of core talent, many of whom have become prime recruitment targets for Samsung Electronics and other rivals.

Heron Neutron Medical, a subsidiary of semiconductor equipment supplier Hermes-Epitek, is set to list on Taiwan’s stock market in mid-September. Heron General Manager Leo Shen stated that by integrating patented technologies from National Tsing Hua University and Taiwan’s Industrial Technology Research Institute (ITRI), the company has developed a patented accelerator-based boron neutron capture therapy (AB-BNCT) device for cancer treatment. This device received medical device certification in 2024, making Heron the first certified manufacturer in Taiwan and the second worldwide.